Literature DB >> 25852053

The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.

A John Barrett1, Sawa Ito1.   

Abstract

The introduction of tyrosine kinase inhibitors (TKIs), a treatment of chronic myelogenous leukemia (CML), has largely replaced curative strategies based on allogeneic stem cell transplantation (SCT). Nevertheless, SCT still remains an option for accelerated/blastic-phase and selected chronic-phase CML. Transplant outcomes can be optimized by peritransplant TKIs, conditioning regimen, BCR-ABL monitoring, and relapse management. Controversies exist in transplant timing, pediatric CML, alternative donors, and economics. SCT continues to serve as a platform of "operational cure" for CML with TKIs and immunotherapies.

Entities:  

Mesh：

Year:  2015        PMID： 25852053      PMCID： PMC4440879          DOI： 10.1182/blood-2014-10-567784

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  92 in total

1.  Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia.

Authors:  A J Barrett; O Ringdén; M J Zhang; A Bashey; J Y Cahn; M S Cairo; R P Gale; A Gratwohl; F Locatelli; R Martino; K R Schultz; P Tiberghien
Journal:  Blood       Date:  2000-06-01       Impact factor: 22.113

2.  The significance of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia.

Authors:  John M Goldman
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-01       Impact factor: 5.742

3.  Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors.

Authors:  Margaret F Bevans; Sandra A Mitchell; John A Barrett; Michael R Bishop; Richard Childs; Daniel Fowler; Michael Krumlauf; Patricia Prince; Nonniekaye Shelburne; Leslie Wehrlen; Li Yang
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-17       Impact factor: 5.742

4.  The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Authors: 
Journal:  Blood       Date:  2013-04-25       Impact factor: 22.113

5.  Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.

Authors:  Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Sergio A Giralt; Mary Beth Rios; Jianqin Shan; Francis J Giles; Deborah A Thomas; Stefan Faderl; Marcos De Lima; Guillermo Garcia-Manero; Richard Champlin; Ralph Arlinghaus; Moshe Talpaz
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

6.  Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.

Authors:  G Weber; U Gerdemann; I Caruana; B Savoldo; N F Hensel; K R Rabin; E J Shpall; J J Melenhorst; A M Leen; A J Barrett; C M Bollard
Journal:  Leukemia       Date:  2013-03-01       Impact factor: 11.528

Review 7.  Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.

Authors:  Elias Jabbour; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2014-05       Impact factor: 10.047

8.  Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.

Authors:  Saar Gill; Sarah K Tasian; Marco Ruella; Olga Shestova; Yong Li; David L Porter; Martin Carroll; Gwenn Danet-Desnoyers; John Scholler; Stephan A Grupp; Carl H June; Michael Kalos
Journal:  Blood       Date:  2014-03-04       Impact factor: 22.113

Review 9.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113

10.  Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.

Authors:  Harald Herrmann; Irina Sadovnik; Sabine Cerny-Reiterer; Thomas Rülicke; Gabriele Stefanzl; Michael Willmann; Gregor Hoermann; Martin Bilban; Katharina Blatt; Susanne Herndlhofer; Matthias Mayerhofer; Berthold Streubel; Wolfgang R Sperr; Tessa L Holyoake; Christine Mannhalter; Peter Valent
Journal:  Blood       Date:  2014-04-28       Impact factor: 22.113
View more
  18 in total

Review 1.  We do still transplant CML, don't we?

Authors:  Charles F Craddock
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Longer delay of hematological recovery and increased transfusion needs after haploidentical compared to non-haploidentical stem cell transplantation.

Authors:  A Desjonqueres; M Illiaquer; A Duquesne; Y Le Bris; P Peterlin; T Guillaume; J Delaunay; F Rialland; P Moreau; M C Béné; P Chevallier; M Eveillard
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

3.  Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party.

Authors:  C Koenecke; D Heim; A van Biezen; M Heuser; M Aljurf; S Kyrcz-Krzemien; L Volin; C A de Souza; T Gedde-Dahl; H Sengeloev; U Schanz; M Komarnicki; C H Arroyo; E Tholouli; E Gluckman; A Esquirol; I Yakoub-Agha; G Gürman; E Olavarria; N Kröger
Journal:  Bone Marrow Transplant       Date:  2016-04-25       Impact factor: 5.483

4.  All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: a retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand.

Authors:  P Kruger; J Cooney; I Nivison-Smith; A Dodds; P Bardy; D Ma; J Szer; S Durrant
Journal:  Bone Marrow Transplant       Date:  2016-05-23       Impact factor: 5.483

5.  Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.

Authors:  Naoto Takahashi; Tetsuzo Tauchi; Kunio Kitamura; Koichi Miyamura; Yoshio Saburi; Yoshihiro Hatta; Yasuhiko Miyata; Shinichi Kobayashi; Kensuke Usuki; Itaru Matsumura; Yosuke Minami; Noriko Usui; Tetsuya Fukuda; Satoru Takada; Maho Ishikawa; Katsumichi Fujimaki; Hiroshi Gomyo; Osamu Sasaki; Kohshi Ohishi; Takaaki Miyake; Kiyotoshi Imai; Hitoshi Suzushima; Hideki Mitsui; Kazuto Togitani; Toru Kiguchi; Yoshiko Atsuta; Shigeki Ohtake; Kazunori Ohnishi; Yukio Kobayashi; Hitoshi Kiyoi; Yasushi Miyazaki; Tomoki Naoe
Journal:  Int J Hematol       Date:  2017-09-19       Impact factor: 2.490

Review 6.  Treatment-free remission in patients with chronic myeloid leukemia.

Authors:  Delphine Rea; Jean-Michel Cayuela
Journal:  Int J Hematol       Date:  2017-07-08       Impact factor: 2.490

Review 7.  Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication.

Authors:  Nur Hezrin Shahrin; Carol Wadham; Susan Branford
Journal:  Curr Hematol Malig Rep       Date:  2022-08-06       Impact factor: 4.213

8.  Case of relentless chronic phase of chronic myeloid leukaemia.

Authors:  Onyee Chan; Hao Chen; Ravitharan Krishnadasan; Faiz Anwer
Journal:  BMJ Case Rep       Date:  2016-06-22

Review 9.  Immunological off-target effects of imatinib.

Authors:  Laurence Zitvogel; Sylvie Rusakiewicz; Bertrand Routy; Maha Ayyoub; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2016-03-31       Impact factor: 66.675

10.  Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells.

Authors:  Ying Lu; Ling-Ling Liu; Shou-Sheng Liu; Zhi-Gang Fang; Yong Zou; Xu-Bin Deng; Zi-Jie Long; Quentin Liu; Dong-Jun Lin
Journal:  J Transl Med       Date:  2016-09-20       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.